henhaobio
Sign in

bioRxivImmunologyPreprint

Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19

A. E. Oja, A. Saris, C. A. Ghandour, N. A. M. Kragten, B. M. Hogema, E. J. Nossent, L. M. A. Heunks, S. Cuvalay, E. Slot, F. H. Swaneveld, H. Vrielink, T. Rispens, E. van der Schoot, R. A. W. van Lier, A. Ten Brinke, P. Hombrink

PDFDOI

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. Understanding both the immunological processes providing specific immunity and potential immunopathology underlying the pathogenesis of this disease may provide valuable insights for potential therapeutic interventions. Here, we quantified SARS-CoV-2 specific immune responses in patients with different clinical courses. Compared to individuals with a mild clinical presentation, CD4+ T cell responses were qualitatively impaired in critically ill patients. Strikingly, however, in these patients the specific IgG antibody response was remarkably strong. The observed disparate T and B cell responses could be indicative of a deregulated immune response in critically ill COVID-19 patients.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.